Table 1.

Baseline demographic and clinical characteristics of patients with Essential tremor

	Patient	Sex, age (yrs)	Disease duration (yrs)	Time since surgery for VIM-DBS (months)	FTM total score (baseline)a	Medication (dosage/day)	tACS frequency (Hz)	VIM-DBS settings (contact/pulse width/amplitude)
ET with VIM-DBS	01	M, 61	10	48	41	–	180	1–2-C + / 60 μs/3.8 V
	02	M, 73	18	26	35	Propanolol 100 mg	130	1–2 + /120 μs/3.5 V
	03	M, 67	12	24	26	Topiramate 50 mg, Primidone 250 mg	130	1-C + /60 μs/3.7 V
	04	F, 47	27	15	11	Propanolol 80 mg, Gabapentin 300 mg	130	2-C + /60 μs/3.0 V
	05	M, 56	40	12	19	–	180	0–1 + / 90 μs/4 V
	06	M, 29	12	10	17	–	130	0-C + /60 μs us/3.0 V
	07	M, 69	49	30	36	–	130	2-C + /60 μs/2.8 V
	08	M, 69	22	93	18	–	180	1–0 + /60 μs/4.0 V
	09	F, 41	26	12	28	Propanolol 40 mg, Topiramate 25 mg, Gabapentin 300 mg	130	0-C + /60 μs/2.8 V
	10	F, 72	16	55	26	–	130	1–2 + /60 μs/3.6 V
	11	M, 44	34	36	42	Topiramate 50 mg	180	1-C + /60 μs/3.9 V
	Mean (SD)	57.1 (14.8)	24.2 (12.6)	32.8 (24.9)	27.2 (10.3)
ET without VIM-DBS	12	M, 68	46	–	34	Propanolol 120 mg, Gabapentin 600 mg	130
	13	M, 70	12	–	26	Propanolol 100 mg	130
	14	M, 74	46	–	23	Topiramate 50 mg, Primidone 50 mg	130
	15	M, 66	52	–	28	–	130
	16	M, 52	12	–	21	Propanolol 60 mg	130
	17	M, 71	17	–	19	Propanolol 40 mg	130
	18	M, 71	42	–	29	Propanolol 40 mg	130
	19	F, 71	15	–	23	Propanolol 100 mg	130
	20	M, 61	53	–	32	Propanolol 80 mg	130
	21	F, 42	12	–	33	–	130
	Mean (SD)	64.6 (10.2)	30.7 (18.3)	–	26.8 (5.2)

VIM-DBS: Ventral Intermediate Thalamic Deep Brain Stimulation, F: female, M: male

^aOFF VIM-DBS for at least 3 h for patients with VIM DBS